Home » Drug Information » FDA-Approved Drugs » 1998
Medical Areas: Cardiology/Vascular Diseases | Endocrinology | Immunology/Infectious Diseases
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Roche
Approval Status: Approved February 1998
Treatment Area: prevention of organ rejection inpatients undergoing heart transplants
CellCept when used in combination with cyclosporine and
corticosteroids has been approved for the prevention of organ
rejection inpatients undergoing heart transplants. CellCept has
previously been approved for the prevention of organ rejection in
kidney-transplant patients.
The principal adverse reactions associated with the
administration of Cell Cept include diarrhea, leukopenia (reduction
of white blood cells), sepsis, and vomiting, and there is evidence
of a higher frequency of certain types of infections.
